Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 4:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 44 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Imiquimod 5% Cream Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5%

NCT00176943
View directory record Official record
Conditions
Alopecia Areata
Interventions
Aldara Cream 5%
Drug
Lead sponsor
Hordinsky, Maria K., MD
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 5, 2026, 4:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases

NCT01421017
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Interventions
Radiation, Imiquimod, Cyclophosphamide
Radiation · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 5, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal

NCT00638651
View directory record Official record
Conditions
Healthy
Interventions
1064 nm Nd:YAG laser, Imiquimod, 5% cream
Device · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 5, 2026, 4:10 AM EDT
Completed Phase 1 Interventional

Pilot Study of DRibble Vaccine for Prostate Cancer Patients

NCT02234921
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Cyclophosphamide, DRibble Vaccine, HPV Vaccinations, Imiquimod
Drug · Biological
Lead sponsor
UbiVac
Industry
Eligibility
Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 5, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Results available

Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases

NCT00899574
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Imiquimod
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 5, 2026, 4:10 AM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL

NCT02689726
View directory record Official record
Conditions
HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL
Interventions
GTL001+, Aldara
Drug
Lead sponsor
Genticel
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Louisville, Kentucky • Raleigh, North Carolina • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 5, 2026, 4:10 AM EDT
Completed Phase 1 Interventional

Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer

NCT00079300
View directory record Official record
Conditions
Non-melanomatous Skin Cancer
Interventions
imiquimod, conventional surgery
Drug · Procedure
Lead sponsor
National Naval Medical Center
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2013 · Synced Oct 5, 2026, 4:10 AM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Basal Cell Carcinoma Chemoprevention Trial

NCT05212246
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
5% Imiquimod cream, Placebo Vehicle Control Cream
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
1,630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 5, 2026, 4:10 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies

NCT02224599
View directory record Official record
Conditions
Progressive Solid Malignancies, Refractory Solid Malignancies, Cancer
Interventions
TAPA-pulsed DC vaccine, Cyclophosphamide Pill, Imiquimod Topical Cream
Biological · Drug
Lead sponsor
Kiromic BioPharma Inc.
Industry
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 5, 2026, 4:10 AM EDT
Completed Phase 3 Interventional Results available

Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis

NCT00948428
View directory record Official record
Conditions
Actinic Keratoses
Interventions
imiquimod, Aldara™, Vehicle Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Hot Springs, Arkansas • Fresno, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 5, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immunologic Profile of Chronically Photodamaged Skin

NCT02889159
View directory record Official record
Conditions
Photoaged Skin, Normal Skin
Interventions
Candida albicans antigen, histamine phosphate, imiquimod 5% cream, Tape Stripping
Biological · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 5, 2026, 4:10 AM EDT
Recruiting Early Phase 1 Interventional

Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides

NCT05838599
View directory record Official record
Conditions
Mycosis Fungoides
Interventions
Imiquimod, Radiation Therapy
Drug · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 5, 2026, 4:10 AM EDT
Completed Phase 4 Interventional Results available

Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis

NCT00116649
View directory record Official record
Conditions
Keratosis
Interventions
imiquimod cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
32
States / cities
Phoenix, Arizona • Encino, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2010 · Synced Oct 5, 2026, 4:10 AM EDT
Completed Phase 1 Interventional

Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma

NCT01264731
View directory record Official record
Conditions
Melanoma
Interventions
MELITAC 12.1, Imiquimod
Biological · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 5, 2026, 4:10 AM EDT
Completed Not applicable Interventional Results available

Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna

NCT00707174
View directory record Official record
Conditions
Cancer, Lentigo Maligna
Interventions
Imiquimod Cream, Tazarotene Cream 0.1%
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Oct 5, 2026, 4:10 AM EDT
Terminated Phase 1 Interventional

Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer

NCT03982004
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Epicutaneous cryoimmunotherapy, Topical imiquimod, Pembrolizumab, Dermatologic Quality of Life Index, Functional Assessment of Cancer Therapy, Intra-lesional GM-CSF, Cry-AC, Cutaneous tumor biopsy, Peripheral blood draw for research
Device · Drug · Other + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 5, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

NCT03180684
View directory record Official record
Conditions
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, Vulvar Intraepithelial Neoplasia (VIN), VIN2, VIN3, Pre-cancerous Lesions of the Vulva, Human Papillomavirus (HPV)
Interventions
VGX-3100, Imiquimod 5% Cream, CELLECTRA™ 2000
Biological · Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Newark, Delaware • Augusta, Georgia • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 5, 2026, 4:10 AM EDT
Completed Early Phase 1 Interventional

Topical Vitamin C for Treatment of Basal Cell Cancer

NCT04279535
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
Topical Ascorbic Acid
Drug
Lead sponsor
Center for Biomedical Research, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 5, 2026, 4:10 AM EDT
Completed Phase 1 Interventional

Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor

NCT01171469
View directory record Official record
Conditions
Brain Tumor, Glioblastoma, Medulloblastoma, Ependymoma, Anaplastic Astrocytoma
Interventions
Dendritic Cells, Imiquimod
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 5, 2026, 4:10 AM EDT
Terminated Phase 2 Interventional Results available

Imiquimod for Preventing Keloid Recurrence

NCT03760250
View directory record Official record
Conditions
Keloid
Interventions
Imiquimod 5% cream
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 5, 2026, 4:10 AM EDT